Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti-inflammatory properties in laboratory studies. In the past 4 months, numerous, controlled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin. A comprehensive scientific review of these referenced trials can be found on the Open Science Foundation pre-print server here: https://osf.io/wx3zn/
Properties of Ivermectin
Ivermectin inhibits the replication of many viruses, including SARS-CoV-2, influenza, and others;
Ivermectin has potent anti-inflammatory properties with multiple mechanisms of inhibition;
Ivermectin diminishes viral load and protects against organ damage in animal models;
Ivermectin prevents transmission of COVID-19 when taken either pre- or post-exposure;
Ivermectin hastens recovery and decreases hospitalization and mortality in patients with COVID-19;
Ivermectin leads to far lower case-fatality rates in regions with widespread use.